LumiThera has announced it has received a $2.3 million pound grant from NIH in USA to continue.
This is important news and continues to support the good news that an effective treatment for dry Macular degeneration appears to be emerging.
Treatment centres are continuing to emerge around the country to offer this treatment locally to patients.
"LumiThera Inc., medical device company commercializing a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI) of up to $2.3M in funding over two years.
The NIH/NEI grant supports an open-label human clinical trial in U.S. intermediate dry age-related macular degeneration (dry AMD) subjects that participated in the pivotal LIGHTSITE III trial. LIGHTSITE IIIB will treat patients for 4 rounds of treatment over fourteen months. Sham patients in the previous study will be able to cross over and begin PBM treatment.
The LIGHTSITE IIIB extension trial follows the successfully completed LIGHTSITE III trial, which showed a sustained, mean increase in best corrected vision acuity (BCVA) letter score of >5.0 letters from baseline at the 13- and 24-month timepoints (p < 0.0001) using the Company's Valeda® Light Delivery System. The study demonstrated disease slowing benefits as fewer PBM-treated eyes progressed to new geographic atrophy (GA), a later disease stage that is associated with permanent loss of retinal tissue and scar. The 24-month optical coherence tomography (OCT) imaging of the
retina indicated that only 6.8% of the PBM group had progressed to new GA, whereas 24% in the sham group developed new GA."
For further information look at Lumithera website
https://eu.lumithera.com/category/press-releases/
Valeda PhotoBioModulation treatment update